dr. petrylak on psma adc for patients with mcrpc
Published 10 years ago • 174 plays • Length 1:05Download video MP4
Download video MP3
Similar videos
-
1:23
dr. petrylak on a phase ii trial of psma adc in taxane-treated mcrpc
-
0:50
psma adc for prostate cancer
-
1:55
dr. petrylak discusses psma-directed therapies in prostate cancer
-
0:34
dr. petrylak discusses custirsen as a potential treatment for prostate cancer
-
1:06
psma adc in prostate cancer: phase i results
-
1:10
dr. daniel petrylak discusses chemotherapy in prostate cancer
-
1:43
dr. petrylak on imaging approaches in prostate cancer
-
1:11
dr. daniel petrylak on orteronel (tak-700) plus docetaxel in prostate cancer
-
15:29
how much time do you have to treat #prostatecancer? | #markscholzmd #alexscholz #pcri
-
13:58
what is the best way to see if prostate cancer has spread?
-
14:39
new fda approved parp inhibitor: talzenna (talazoparib) & xtandi | #markscholzmd #alexscholz #pcri
-
14:09
how psma revolutionizes staging for #prostatecancer | #markscholzmd | #pcri
-
1:08
dr. daniel petrylak explains the correlation between immune response to sipuleucel-t and survival
-
1:01
dr. petrylak on novel imaging modalities in prostate cancer
-
32:05
2021: psma and prostate imaging | dr. thomas hope | 2021 moyad scholz mid-year update | pcri
-
1:21
dr. petrylak explains prostate cancer clinical trial difficulties
-
1:18
dr. petrylak on the role of psa screening in prostate cancer
-
18:26
psma & newly-diagnosed #prostatecancer | markscholzmd #alexscholz #pcri
-
0:47
dr. petrylak on the recent developments in prostate cancer
-
0:57
dr. petrylak on immunotherapy in bladder cancer
-
1:47
dr. petrylak on sequencing of targeted agents in bladder cancer
-
8:30
monitoring patients during treatment for advanced prostate cancer